Nasdaq:US$16.32 (+0.02) | HKEX:HK$26.35 (+0.50) | AIM:£2.45 (-0.03)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer